MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
1.170
+0.180
+18.17%
After Hours: 1.160 -0.01 -0.85% 19:51 05/01 EDT
OPEN
1.020
PREV CLOSE
0.9901
HIGH
1.190
LOW
1.000
VOLUME
2.42M
TURNOVER
--
52 WEEK HIGH
2.110
52 WEEK LOW
0.8319
MARKET CAP
112.11M
P/E (TTM)
-1.1662
1D
5D
1M
3M
1Y
5Y
1D
Immunic Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 16h ago
Promising Phase 2 Results for Vidofludimus Calcium in Progressive Multiple Sclerosis Highlight Potential for Neuroprotection and Disease Modification
TipRanks · 18h ago
Immunic price target raised to $22 from $19 at Brookline
TipRanks · 1d ago
Immunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
TipRanks · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Immunic Is Maintained at Buy by D. Boral Capital
Dow Jones · 1d ago
Immunic Price Target Maintained With a $17.00/Share by D. Boral Capital
Dow Jones · 1d ago
D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target
Benzinga · 1d ago
More
About IMUX
More
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Recently
Symbol
Price
%Change

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.